Revision of Applications for Manufacturing and Procurement Quotas
Built by the Tribune's code from the Federal Register. No AI wrote this page. Published in the Federal Register May 20, 2026. Document 2026-10128. Updated Nov. 11, 2026.
- What it does
The Drug Enforcement Administration (DEA) proposes to revise existing regulations relating to the management of quotas for schedule I and II controlled substances and the list I chemicals, ephedrine, pseudoephedrine, and phenylpropanolamine, to be utilized by DEA- registered manufacturers. This rule is being proposed to: restructure DEA's manufacturing and procurement quota regulations for more clarity and consistency; clarify which use-specific subcategories for quotas should be used for controlled substances that will be sold domestically and controlled substances that will be exported; and revise the applications for individual manufacturing and procurement quota. The changes are necessary to increase visibility into the controlled substance supply chain by providing DEA with more detailed information allowing the agency to react more precisely in preventing drug shortages; and to ensure that enough of the schedule I and II controlled substances and three list I chemicals can be manufactured to meet estimated scientific, medical, lawful export, and inventory needs. This rule also contains revisions to use gender neutral language and other non-substantive revisions.
The Drug Enforcement Administration's summary, as published in the Federal Register.
- What it would change
2 parts of Title 21 of the Code of Federal Regulations:
- Before this
No earlier Federal Register document under regulation identifier 1117-AB86 since Jan. 1, 2025.
- What happens next and when
Comments must be received by July 20, 2026. Commenters should be aware that the electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period.
The agency's dates, word for word.
The record as published
| Document number | 2026-10128 |
|---|---|
| Action | Notice of proposed rulemaking. |
| Agencies | Justice Department; Drug Enforcement Administration |
| Published | May 20, 2026 |
| Comments close | July 20, 2026 |
| Regulation identifier (RIN) | 1117-AB86 |
| Docket | DEA-2026-0793 |
| Significant (marked in the Federal Register) | Yes |
Source: the Federal Register (public domain). The document in the Federal Register